Search
EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation
To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).
Read moreEHA-AAH Balkan Mini Hematology Tutorial 2021
EHA is joining forces with the Albanian Association of Hematology (AAH) to organize the EHA-AAH Balkan Hematology Mini Tutorial.
Read morePractical information
Timelines:Application deadline: September 24, 2024 (15:00 CEST)
Notification of awards: December 2024
When & where do the meetings take place?Workshop 1:
Date: April 22-26, 2025
Venue: Cambridge, UK
CBTH session and EHA Congress:
Date: June 11-15, 2025
Venue: TBC
Workshop 2:
Date:…
Dates and deadlines
You may find in this page all the dates and deadlines related to the EHA2025 Congress. All deadlines, except if mentioned differently, end at 23:59 CET/CEST.
The timelines will be updated regularly.
The importance of education and collaboration for the treatment of patients
This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here
Read moreEHA-Balkan Hematology Day 2021
EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 2nd edition of the EHA-Balkan Hematology Day.
Read more1st European EHA Sickle Cell Conference
EHA is teaming up with the Annual Scientific Conference on Sickle Cell and Thalassaemia, 2020 and the British Society of Haematology (BSH) to co-organize this first European Sickle Cell Conference; and also as a result of COVID-19 offer it as…
Read moreMajor research funding calls are out now
First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- »